RESUMEN
The widespread use of smartphones and the internet has enabled self-monitoring and more hybrid-care models. The COVID-19 pandemic has further accelerated remote monitoring, including in the heterogenous and often vulnerable group of patients with interstitial lung diseases (ILDs). Home monitoring in ILD has the potential to improve access to specialist care, reduce the burden on health-care systems, improve quality of life for patients, identify acute and chronic disease worsening, guide treatment decisions, and simplify clinical trials. Home spirometry has been used in ILD for several years and studies with other devices (such as pulse oximeters, activity trackers, and cough monitors) have emerged. At the same time, challenges have surfaced, including technical, analytical, and implementational issues. In this Series paper, we provide an overview of experiences with home monitoring in ILD, address the challenges and limitations for both care and research, and provide future perspectives. VIDEO ABSTRACT.
Asunto(s)
COVID-19 , Enfermedades Pulmonares Intersticiales , Humanos , Calidad de Vida , Pandemias , Enfermedades Pulmonares Intersticiales/diagnóstico , Enfermedades Pulmonares Intersticiales/terapia , OxígenoRESUMEN
Durante la última década, los avances en el estudio de los mecanismos fisiopatológicos, las posibles vías de acción de nuevas drogas y la puesta en práctica de las mismas son algunos de los factores que contribuyeron al cambio que hemos observado en el manejo clínico y terapéutico las EPID (enfermedades pulmonares intersticiales difusas). Un mayor entendimiento de dichas enfermedades permitió diferenciar que existen EPID que pueden tener un comportamiento inflamatorio, otras fibrótico o ambos